NR565: Advanced Pharmacology
Fundamentals
Week 4 Midterm Exam Review
Chamberlain University | 2026
125 Questions with Expert Rationales
Instructions
• This review covers advanced pharmacology concepts including pharmacokinetics,
pharmacodynamics, pharmacogenomics, and drug therapy for common conditions.
• Select the single best answer for each question.
• Rationales provide clinical reasoning and evidence-based explanations for each
correct answer.
Section 1: Pharmacokinetics and Pharmacodynamics
(Questions 1-25)
1. A 72-year-old patient with heart failure and hypoalbuminemia is prescribed a
highly protein-bound medication. The NP anticipates which pharmacokinetic
change?
A. Decreased volume of distribution
B. Increased free drug concentration and risk of toxicity
C. Decreased drug half-life
D. Increased first-pass metabolism
Answer: B
Expert Rationale: Hypoalbuminemia reduces protein binding sites, increasing the
,fraction of free (active) drug. Combined with age-related renal decline, this
significantly increases toxicity risk. Older adults also have reduced clearance, further
compounding the risk.
2. A drug has a half-life of 24 hours. Approximately how many days will it take
to reach steady state?
A. 1 day
B. 3 days
C. 5 days
D. 7 days
Answer: C
Expert Rationale: Steady state is achieved after 4-5 half-lives. With a 24-hour
half-life, steady state is reached in about 4-5 days (approximately 5 days).
3. Which statement best describes a competitive antagonist?
A. It binds irreversibly to the receptor and causes permanent inactivation
B. It binds to the same receptor site as the agonist and reversibly blocks it
C. It binds to a different receptor site and enhances the agonist's effect
D. It produces the same maximal response as the agonist
Answer: B
Expert Rationale: A competitive antagonist reversibly binds to the same receptor
site as the agonist, preventing the agonist from binding. Its effects can be overcome
by increasing the concentration of the agonist.
4. A patient is a CYP2D6 poor metabolizer. Which medication would have
reduced efficacy due to impaired activation?
A. Omeprazole
B. Codeine
C. Diazepam
D. Propranolol
Answer: B
Expert Rationale: Codeine is a prodrug requiring CYP2D6-mediated conversion
to its active metabolite, morphine. Poor metabolizers have reduced conversion,
leading to inadequate analgesia. Ultra-rapid metabolizers are at risk for toxicity.
5. The NP prescribes a medication with high first-pass metabolism. Which route
of administration would completely bypass this effect?
A. Oral
B. Sublingual
C. Intravenous
D. Both B and C
,Answer: D
Expert Rationale: First-pass metabolism occurs when drugs are absorbed from
the GI tract and pass through the liver via the portal vein. Sublingual and intravenous
routes bypass the portal circulation, avoiding first-pass metabolism.
6. A patient with renal impairment (eGFR 25 mL/min) requires a medication
that is primarily renally excreted. What adjustment is most appropriate?
A. Increase the dose to achieve therapeutic levels
B. Decrease the dose and/or increase the dosing interval
C. No adjustment is needed
D. Administer the drug via a different route
Answer: B
Expert Rationale: For renally excreted drugs, impaired renal function leads to
drug accumulation. Dose reduction or prolongation of the dosing interval is required
to prevent toxicity.
7. A patient develops an anaphylactic reaction to penicillin. This is classified as
which type of adverse drug reaction?
A. Type A (augmented)
B. Type B (bizarre)
C. Type C (chronic)
D. Type D (delayed)
Answer: B
Expert Rationale: Type B reactions are unpredictable, not dose-related, and often
related to patient-specific factors such as immunologic hypersensitivity. Anaphylaxis
is a classic Type B reaction.
8. The NP is prescribing a drug that is a P-glycoprotein (P-gp) substrate. What
is the function of P-gp?
A. It metabolizes drugs in the liver
B. It transports drugs back into the intestinal lumen, reducing absorption
C. It increases drug distribution to the brain
D. It enhances renal drug excretion
Answer: B
Expert Rationale: P-glycoprotein is an efflux transporter located in the intestines,
blood-brain barrier, and kidneys. In the gut, it pumps drugs back into the lumen,
reducing oral bioavailability.
9. A drug with a narrow therapeutic index requires therapeutic drug
monitoring. Which drug fits this description?
A. Metformin
, B. Lithium
C. Lisinopril
D. Amoxicillin
Answer: B
Expert Rationale: Lithium has a narrow therapeutic index (0.6-1.2 mEq/L). Levels
outside this range can lead to toxicity or therapeutic failure. Regular monitoring is
essential.
10. Which drug property most facilitates crossing the blood-brain barrier?
A. High polarity
B. High lipophilicity and low molecular weight
C. High protein binding
D. High water solubility
Answer: B
Expert Rationale: The blood-brain barrier is composed of tight junctions.
Lipophilic, non-polar, low molecular weight drugs can diffuse across cell membranes
more readily than hydrophilic, polar, or large molecules.
11. A patient is started on a medication that is a CYP3A4 inhibitor. Which drug-
drug interaction should the NP anticipate?
A. Decreased levels of CYP3A4 substrates
B. Increased levels of CYP3A4 substrates
C. No change in drug levels
D. Increased metabolism of the inhibitor
Answer: B
Expert Rationale: CYP3A4 inhibitors (e.g., ketoconazole, grapefruit juice)
decrease the metabolism of CYP3A4 substrates, leading to increased drug levels and
potential toxicity.
12. Which physiologic change in older adults most significantly affects drug
distribution?
A. Increased total body water
B. Decreased serum albumin and increased body fat
C. Increased hepatic blood flow
D. Increased glomerular filtration rate
Answer: B
Expert Rationale: Aging is associated with decreased serum albumin (increasing
free drug levels for protein-bound drugs) and increased body fat (increasing volume
of distribution for lipophilic drugs).
Fundamentals
Week 4 Midterm Exam Review
Chamberlain University | 2026
125 Questions with Expert Rationales
Instructions
• This review covers advanced pharmacology concepts including pharmacokinetics,
pharmacodynamics, pharmacogenomics, and drug therapy for common conditions.
• Select the single best answer for each question.
• Rationales provide clinical reasoning and evidence-based explanations for each
correct answer.
Section 1: Pharmacokinetics and Pharmacodynamics
(Questions 1-25)
1. A 72-year-old patient with heart failure and hypoalbuminemia is prescribed a
highly protein-bound medication. The NP anticipates which pharmacokinetic
change?
A. Decreased volume of distribution
B. Increased free drug concentration and risk of toxicity
C. Decreased drug half-life
D. Increased first-pass metabolism
Answer: B
Expert Rationale: Hypoalbuminemia reduces protein binding sites, increasing the
,fraction of free (active) drug. Combined with age-related renal decline, this
significantly increases toxicity risk. Older adults also have reduced clearance, further
compounding the risk.
2. A drug has a half-life of 24 hours. Approximately how many days will it take
to reach steady state?
A. 1 day
B. 3 days
C. 5 days
D. 7 days
Answer: C
Expert Rationale: Steady state is achieved after 4-5 half-lives. With a 24-hour
half-life, steady state is reached in about 4-5 days (approximately 5 days).
3. Which statement best describes a competitive antagonist?
A. It binds irreversibly to the receptor and causes permanent inactivation
B. It binds to the same receptor site as the agonist and reversibly blocks it
C. It binds to a different receptor site and enhances the agonist's effect
D. It produces the same maximal response as the agonist
Answer: B
Expert Rationale: A competitive antagonist reversibly binds to the same receptor
site as the agonist, preventing the agonist from binding. Its effects can be overcome
by increasing the concentration of the agonist.
4. A patient is a CYP2D6 poor metabolizer. Which medication would have
reduced efficacy due to impaired activation?
A. Omeprazole
B. Codeine
C. Diazepam
D. Propranolol
Answer: B
Expert Rationale: Codeine is a prodrug requiring CYP2D6-mediated conversion
to its active metabolite, morphine. Poor metabolizers have reduced conversion,
leading to inadequate analgesia. Ultra-rapid metabolizers are at risk for toxicity.
5. The NP prescribes a medication with high first-pass metabolism. Which route
of administration would completely bypass this effect?
A. Oral
B. Sublingual
C. Intravenous
D. Both B and C
,Answer: D
Expert Rationale: First-pass metabolism occurs when drugs are absorbed from
the GI tract and pass through the liver via the portal vein. Sublingual and intravenous
routes bypass the portal circulation, avoiding first-pass metabolism.
6. A patient with renal impairment (eGFR 25 mL/min) requires a medication
that is primarily renally excreted. What adjustment is most appropriate?
A. Increase the dose to achieve therapeutic levels
B. Decrease the dose and/or increase the dosing interval
C. No adjustment is needed
D. Administer the drug via a different route
Answer: B
Expert Rationale: For renally excreted drugs, impaired renal function leads to
drug accumulation. Dose reduction or prolongation of the dosing interval is required
to prevent toxicity.
7. A patient develops an anaphylactic reaction to penicillin. This is classified as
which type of adverse drug reaction?
A. Type A (augmented)
B. Type B (bizarre)
C. Type C (chronic)
D. Type D (delayed)
Answer: B
Expert Rationale: Type B reactions are unpredictable, not dose-related, and often
related to patient-specific factors such as immunologic hypersensitivity. Anaphylaxis
is a classic Type B reaction.
8. The NP is prescribing a drug that is a P-glycoprotein (P-gp) substrate. What
is the function of P-gp?
A. It metabolizes drugs in the liver
B. It transports drugs back into the intestinal lumen, reducing absorption
C. It increases drug distribution to the brain
D. It enhances renal drug excretion
Answer: B
Expert Rationale: P-glycoprotein is an efflux transporter located in the intestines,
blood-brain barrier, and kidneys. In the gut, it pumps drugs back into the lumen,
reducing oral bioavailability.
9. A drug with a narrow therapeutic index requires therapeutic drug
monitoring. Which drug fits this description?
A. Metformin
, B. Lithium
C. Lisinopril
D. Amoxicillin
Answer: B
Expert Rationale: Lithium has a narrow therapeutic index (0.6-1.2 mEq/L). Levels
outside this range can lead to toxicity or therapeutic failure. Regular monitoring is
essential.
10. Which drug property most facilitates crossing the blood-brain barrier?
A. High polarity
B. High lipophilicity and low molecular weight
C. High protein binding
D. High water solubility
Answer: B
Expert Rationale: The blood-brain barrier is composed of tight junctions.
Lipophilic, non-polar, low molecular weight drugs can diffuse across cell membranes
more readily than hydrophilic, polar, or large molecules.
11. A patient is started on a medication that is a CYP3A4 inhibitor. Which drug-
drug interaction should the NP anticipate?
A. Decreased levels of CYP3A4 substrates
B. Increased levels of CYP3A4 substrates
C. No change in drug levels
D. Increased metabolism of the inhibitor
Answer: B
Expert Rationale: CYP3A4 inhibitors (e.g., ketoconazole, grapefruit juice)
decrease the metabolism of CYP3A4 substrates, leading to increased drug levels and
potential toxicity.
12. Which physiologic change in older adults most significantly affects drug
distribution?
A. Increased total body water
B. Decreased serum albumin and increased body fat
C. Increased hepatic blood flow
D. Increased glomerular filtration rate
Answer: B
Expert Rationale: Aging is associated with decreased serum albumin (increasing
free drug levels for protein-bound drugs) and increased body fat (increasing volume
of distribution for lipophilic drugs).
